Abstract | OBJECTIVE: METHODS: Patients with refractory schizophrenia were assigned to clozapine (n=85) or haloperidol (n=96) and followed for 3 months. Symptom improvement was evaluated by Positive and Negative Syndrome Scale score. Six markers at DTNBP1 and 38 ancestry-informative markers were genotyped in all participants. The relationships between the effects of antipsychotics and the diplotypes, haplotypes, genotypes, and alleles of DTNBP1 were tested by analysis of covariance, analysis of variance, and t-test. RESULTS: Patients with diplotype ACCCTC/GTTGCC, genotypes T/T+T/C, or allele T of marker rs742105 (P1333) have better response to clozapine (0.005< or =P< or =0.049), and patients with diplotype ACCCTC/GCCGCC, genotype A/G, or allele A of marker rs909706 (P1583) have better response to haloperidol (0.007< or =P< or =0.080) in European-Americans, African-Americans, and/or the combined sample; European-American patients with diplotype ACCCTC/GCCGCC have worse response to clozapine on positive symptoms (P=0.011). CONCLUSION:
|
Authors | Lingjun Zuo, Xingguang Luo, John H Krystal, Joyce Cramer, Dennis S Charney, Joel Gelernter |
Journal | Pharmacogenetics and genomics
(Pharmacogenet Genomics)
Vol. 19
Issue 6
Pg. 437-46
(Jun 2009)
ISSN: 1744-6872 [Print] United States |
PMID | 19369910
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Antipsychotic Agents
- Carrier Proteins
- DTNBP1 protein, human
- Dysbindin
- Dystrophin-Associated Proteins
- Clozapine
- Haloperidol
|
Topics |
- Black or African American
- Antipsychotic Agents
(therapeutic use)
- Carrier Proteins
(genetics)
- Clozapine
(therapeutic use)
- Double Bind Interaction
- Dysbindin
- Dystrophin-Associated Proteins
- Genetic Variation
- Genotype
- Haloperidol
(therapeutic use)
- Haplotypes
- Humans
- Schizophrenia
(drug therapy, metabolism)
- Treatment Outcome
- White People
|